CY1111934T1 - Σταθεροποιημενες φαρμακευτικες συνθεσεις οι οποιες περιεχουν φεσοτεροδινη - Google Patents

Σταθεροποιημενες φαρμακευτικες συνθεσεις οι οποιες περιεχουν φεσοτεροδινη

Info

Publication number
CY1111934T1
CY1111934T1 CY20111100983T CY111100983T CY1111934T1 CY 1111934 T1 CY1111934 T1 CY 1111934T1 CY 20111100983 T CY20111100983 T CY 20111100983T CY 111100983 T CY111100983 T CY 111100983T CY 1111934 T1 CY1111934 T1 CY 1111934T1
Authority
CY
Cyprus
Prior art keywords
fesoterodin
pharmaceutical compositions
compositions containing
stable pharmaceutical
fesoterodine
Prior art date
Application number
CY20111100983T
Other languages
English (en)
Inventor
Dr Christoph Arth
Dr Hans-Jürgen Mika
Dr Michael Komenda
Dr Hans Lindner
Dr Fatima Bicane
Dr Kerstin Paulus
Dr Meike Irngartigner
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111934(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of CY1111934T1 publication Critical patent/CY1111934T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα αίτηση αναφέρεται σε μία φαρμακευτική σύνθεση η οποία περιέχει φεσοτεροδίνη ή ένα φαρμακευτικά αποδεκτό άλας ή ένωση διαλύματος αυτής και ένα σταθεροποιητή που επιλέγεται από την ομάδα που συνίσταται από την ξυλιτόλη, τη σορβιτόλη, την πολυδεξτρόζη, την ισομαλτιτόλη και τη δεξτρόζη.
CY20111100983T 2006-06-09 2011-10-17 Σταθεροποιημενες φαρμακευτικες συνθεσεις οι οποιες περιεχουν φεσοτεροδινη CY1111934T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06011942 2006-06-09
EP06011943 2006-06-09
EP06011941 2006-06-09
EP07729956A EP2029134B1 (en) 2006-06-09 2007-06-06 Stabilized pharmaceutical compositions comprising fesoterodine

Publications (1)

Publication Number Publication Date
CY1111934T1 true CY1111934T1 (el) 2015-11-04

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100983T CY1111934T1 (el) 2006-06-09 2011-10-17 Σταθεροποιημενες φαρμακευτικες συνθεσεις οι οποιες περιεχουν φεσοτεροδινη

Country Status (37)

Country Link
EP (1) EP2029134B1 (el)
JP (2) JP4743321B2 (el)
KR (1) KR101316773B1 (el)
CN (1) CN101466371B (el)
AP (1) AP2416A (el)
AR (1) AR061289A1 (el)
AT (1) ATE517619T1 (el)
AU (1) AU2007255408B2 (el)
BR (1) BRPI0712865B1 (el)
CA (1) CA2652712C (el)
CR (1) CR10494A (el)
CU (1) CU23850B1 (el)
CY (1) CY1111934T1 (el)
DK (1) DK2029134T3 (el)
EA (1) EA015909B9 (el)
EC (1) ECSP089010A (el)
ES (1) ES2370943T3 (el)
GT (1) GT200800276A (el)
HR (1) HRP20110776T1 (el)
IL (2) IL195732A (el)
MA (1) MA30504B1 (el)
MX (1) MX2008015736A (el)
MY (1) MY146574A (el)
NI (1) NI200800318A (el)
NL (1) NL2000690C2 (el)
NO (1) NO341980B1 (el)
NZ (1) NZ572616A (el)
PE (2) PE20080331A1 (el)
PL (1) PL2029134T3 (el)
PT (1) PT2029134E (el)
RS (1) RS51973B (el)
SI (1) SI2029134T1 (el)
TN (1) TNSN08505A1 (el)
TW (2) TWI397409B (el)
UY (1) UY30394A1 (el)
WO (1) WO2007141298A1 (el)
ZA (1) ZA200806411B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086103A1 (en) * 2008-04-04 2011-04-14 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
PL2416761T3 (pl) 2009-05-11 2015-07-31 Ratiopharm Gmbh Desfezoterodyna w postaci soli kwasu winowego
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20130172411A1 (en) * 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
WO2013054337A1 (en) * 2011-07-04 2013-04-18 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (en) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
US20150182629A1 (en) * 2012-07-02 2015-07-02 Hetero Research Foundation Stable compositions of fesoterodine
DK2914255T3 (da) 2012-11-02 2021-10-25 Murray & Poole Entpr Ltd Behandling eller forebyggelse af kardiovaskulære hændelser via administration af colchicin
BR112015026418B1 (pt) * 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
WO2019206391A1 (en) 2018-04-26 2019-10-31 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
JPWO2023145486A1 (el) * 2022-01-28 2023-08-03

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002543T2 (tr) * 1998-03-03 2000-11-21 Shionogi & Co., Ltd. Fosfolipaz önleyici sodyum [[3-(2-amino-1,2-dioksietil-1-fenilmetil) -2-etil-1-fenilmetil)- 1H-indol-4-il]oksi] asetat içeren farmasötik kompozisyonlar
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
HK1128626A1 (en) 2009-11-06
TNSN08505A1 (fr) 2010-04-14
CA2652712A1 (en) 2007-12-13
EP2029134B1 (en) 2011-07-27
AP2416A (en) 2012-06-01
NI200800318A (es) 2011-01-12
ES2370943T3 (es) 2011-12-23
UY30394A1 (es) 2007-11-30
SI2029134T1 (sl) 2012-01-31
JP4781489B2 (ja) 2011-09-28
CU20080235A7 (es) 2011-04-26
HRP20110776T1 (hr) 2011-11-30
CN101466371A (zh) 2009-06-24
WO2007141298A1 (en) 2007-12-13
NO20090141L (no) 2009-01-09
AP2008004673A0 (en) 2008-12-31
TW200814992A (en) 2008-04-01
EA200802444A1 (ru) 2009-06-30
ATE517619T1 (de) 2011-08-15
AU2007255408B2 (en) 2013-03-14
TW201336491A (zh) 2013-09-16
NL2000690A1 (nl) 2007-12-11
DK2029134T3 (da) 2011-10-17
JP2009539802A (ja) 2009-11-19
PE20120476A1 (es) 2012-04-20
EA015909B9 (ru) 2012-03-30
BRPI0712865A2 (pt) 2012-12-18
CU23850B1 (es) 2012-10-15
KR20090026135A (ko) 2009-03-11
PL2029134T3 (pl) 2011-12-30
KR101316773B1 (ko) 2013-10-15
CA2652712C (en) 2014-04-01
CN101466371B (zh) 2011-10-05
IL220800A (en) 2015-03-31
NL2000690C2 (nl) 2008-04-01
EP2029134A1 (en) 2009-03-04
PE20080331A1 (es) 2008-06-19
ECSP089010A (es) 2009-01-30
MA30504B1 (fr) 2009-06-01
AU2007255408A1 (en) 2007-12-13
MX2008015736A (es) 2009-01-09
AR061289A1 (es) 2008-08-20
CR10494A (es) 2009-01-19
IL195732A0 (en) 2009-09-01
NZ572616A (en) 2010-11-26
GT200800276A (es) 2009-06-18
RS51973B (en) 2012-02-29
BRPI0712865B1 (pt) 2021-08-17
PT2029134E (pt) 2011-11-02
MY146574A (en) 2012-08-30
TWI520735B (zh) 2016-02-11
NO341980B1 (no) 2018-03-05
JP2011140498A (ja) 2011-07-21
ZA200806411B (en) 2009-05-27
EA015909B1 (ru) 2011-12-30
TWI397409B (zh) 2013-06-01
JP4743321B2 (ja) 2011-08-10
IL195732A (en) 2013-09-30

Similar Documents

Publication Publication Date Title
CY1111934T1 (el) Σταθεροποιημενες φαρμακευτικες συνθεσεις οι οποιες περιεχουν φεσοτεροδινη
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
CY1126116T1 (el) Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
EA201070597A1 (ru) Антибактериальные аналоги аминогликозида
NO20065701L (no) Orodispersibel farmasoytisk sammensetning for oromukosal eller sublingval administrasjon av agomelatin
CY1115253T1 (el) Κρυσταλλικες μορφες ενος παραγωγου 2-θειαζολυλο-4-κινολινυλ-οξυ-ομαδας, ενος ισχυρου αναστολεα του ηcv
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
CY1114504T1 (el) Συνθεσεις τιγεκυκλινης και μεθοδοι παρασκευης
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1122416T1 (el) Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
CY1111129T1 (el) Στερεη φαρμακευτικη ενωση που περιεχει τελιθρομυκινη
ATE537816T1 (de) Leflunomid enthaltende pharmazeutische zusammensetzungen
CY1110089T1 (el) 2-αλκοξυ-3,4,5-τριϋδροξυ-αλκυλαμιδο-βενζοθειαζεπινη, η παρασκευη τους, σε ποιες συνθεσεις περιεχονται και η χρηση τους
GT200600132A (es) Una oxindoloxazolidinona como agente antibacteriano
UA94107C2 (ru) Стабилизированная фармацевтическая композиция фезотеродина
TH109086A (th) ไดฟีนิล-ไดไฮโดร-อิมิดาโซไพริดิโนน